Lyra Therapeutics Inc (NASDAQ: LYRA)’s stock price has dropped by -12.96 in relation to previous closing price of 4.63. Nevertheless, the company has seen a loss of -14.62% in its stock price over the last five trading days. Zacks Investment Research reported 2024-04-30 that Lyra Therapeutics, Inc. (LYRA) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.44 per share a year ago.
Is It Worth Investing in Lyra Therapeutics Inc (NASDAQ: LYRA) Right Now?
The 36-month beta value for LYRA is also noteworthy at 0.31. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for LYRA is 46.53M, and at present, short sellers hold a 0.72% of that float. The average trading volume of LYRA on May 06, 2024 was 368.41K shares.
LYRA’s Market Performance
The stock of Lyra Therapeutics Inc (LYRA) has seen a -14.62% decrease in the past week, with a -23.67% drop in the past month, and a -13.89% fall in the past quarter. The volatility ratio for the week is 13.16%, and the volatility levels for the past 30 days are at 7.71% for LYRA. The simple moving average for the past 20 days is -21.97% for LYRA’s stock, with a -6.97% simple moving average for the past 200 days.
Analysts’ Opinion of LYRA
Many brokerage firms have already submitted their reports for LYRA stocks, with BTIG Research repeating the rating for LYRA by listing it as a “Buy.” The predicted price for LYRA in the upcoming period, according to BTIG Research is $15 based on the research report published on October 06, 2023 of the previous year 2023.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see LYRA reach a price target of $12. The rating they have provided for LYRA stocks is “Buy” according to the report published on August 31st, 2023.
Cantor Fitzgerald gave a rating of “Overweight” to LYRA, setting the target price at $15 in the report published on May 24th of the previous year.
LYRA Trading at -27.04% from the 50-Day Moving Average
After a stumble in the market that brought LYRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -40.65% of loss for the given period.
Volatility was left at 7.71%, however, over the last 30 days, the volatility rate increased by 13.16%, as shares sank -19.72% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.75% lower at present.
During the last 5 trading sessions, LYRA fell by -14.62%, which changed the moving average for the period of 200-days by +36.61% in comparison to the 20-day moving average, which settled at $5.12. In addition, Lyra Therapeutics Inc saw -23.09% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LYRA starting from Waksal Harlan, who purchase 25,000 shares at the price of $2.96 back on Nov 10 ’23. After this action, Waksal Harlan now owns 261,966 shares of Lyra Therapeutics Inc, valued at $74,095 using the latest closing price.
PERCEPTIVE ADVISORS LLC, the Director of Lyra Therapeutics Inc, purchase 3,610,832 shares at $2.49 during a trade that took place back on May 31 ’23, which means that PERCEPTIVE ADVISORS LLC is holding 11,469,117 shares at $8,999,999 based on the most recent closing price.
Stock Fundamentals for LYRA
Current profitability levels for the company are sitting at:
- -43.08 for the present operating margin
- -14.11 for the gross margin
The net margin for Lyra Therapeutics Inc stands at -40.23. The total capital return value is set at -0.55. Equity return is now at value -95.93, with -58.52 for asset returns.
Based on Lyra Therapeutics Inc (LYRA), the company’s capital structure generated 0.23 points at debt to capital in total, while cash flow to debt ratio is standing at -2.35. The debt to equity ratio resting at 0.3. The interest coverage ratio of the stock is 62.61.
Currently, EBITDA for the company is -65.25 million with net debt to EBITDA at -0.07. When we switch over and look at the enterprise to sales, we see a ratio of 157.44. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.78.
Conclusion
In summary, Lyra Therapeutics Inc (LYRA) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
